Table I.
Patient characteristics (n=666).
| Variables | Total | % |
|---|---|---|
| Primary tumor | ||
| Menopausal status | ||
| Premenopausal | 353 | 53.0 |
| Postmenopausal | 313 | 47.0 |
| Nodal status | ||
| N0 | 220 | 33.0 |
| N+ | 426 | 64.0 |
| Unknown | 20 | 3.0 |
| Nuclear grade | ||
| 1 | 119 | 17.9 |
| 2 | 330 | 49.5 |
| 3 | 107 | 16.1 |
| Unknown | 110 | 16.5 |
| ER status | ||
| (+) | 393 | 59.0 |
| (−) | 273 | 41.0 |
| PgR status | ||
| (+) | 271 | 40.7 |
| (−) | 338 | 50.8 |
| Unknown | 57 | 8.5 |
| HER2 status | ||
| (−) | 309 | 46.4 |
| (+) | 125 | 18.8 |
| Unknown | 232 | 34.8 |
| Subtype | ||
| Luminal | 221 | 33.2 |
| Luminal/HER2 | 55 | 8.3 |
| HER2-enriched | 70 | 10.5 |
| Triple-negative | 88 | 13.2 |
| Unknown | 232 | 34.8 |
| Recurrence | ||
| DFI (years) | ||
| <2 | 290 | 43.6 |
| <5 | 224 | 33.6 |
| ≥5 | 152 | 22.8 |
| Recurrence site | ||
| Soft tissue | 260 | 39.1 |
| Bone | 158 | 23.7 |
| Viscera | 248 | 37.2 |
| Primary surgery | ||
| Age (years) | ||
| Mean ± SD | 51.6±12.9 | |
| Tumor size (mm) | ||
| Mean ± SD | 30.7±24.1 | |
ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor 2; DFI, disease-free interval.